Skip Navigation
 
 
 
 

Specialty, Disease or Condition


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z More Search Options
More Search Options
Locations     Health Topic  

Languages

Search all languages or select any specific language(s) from our A-Z listing below.
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z    

Gender

 
Print This Page
Share this page: More
 

Keith William Pratz, MD

Pratz, Keith William, MD
Title(s):
Assistant Professor of Oncology

Appointment Phone:
410-955-8964

Primary Location:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Expertise:
Hematologic Malignancies, Leukemia, Medical Oncology

Education and Experience

Training
  • University of Medicine & Dentistry of New Jersey - (Camden NJ)/ (2002)
Residencies
  • Mayo Clinic Medical School College of Medicine (Rochester MN)/ Internal Medicine (2005)
Fellowships
  • The Johns Hopkins Hospital (Baltimore MD)/ Oncology (2009)
Certifications
  • Medical Oncology, American Board of Internal Medicine (2009)
  • Internal Medicine, American Board of Internal Medicine (2005)

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Baltimore, MD 21231
Phone: 410-502-7726
Appointment Phone: 410-955-8964
Fax: 410-614-1005
Location Map
Department / Division
  • Oncology

Centers/Institutes

Centers / Institutes
  • Sidney Kimmel Comprehensive Cancer Center

Bio

Expertise
  • Hematologic Malignancies
  • Leukemia
  • Medical Oncology

Research

Research Interests
  • My research interests include the development of therapies directed at activated signal transduction systems in cancer. In Acute Myeloid Leukemia (AML) one such activated pathway involves the receptor tyrosine kinase FLT3. FLT3 is mutated in about 1/3 of cases of adult AML and confers a poor prognosis. Several agents are in development targeting FLT3 and our laboratory has developed methods for the determination of the degree to which these compounds inhibit FLT3 over the course of the treatment cycle. We assay target in both circulating leukemia and use a plasma based assay for ex vivo target assessment in patients with insufficient circulating leukemia. We have found that transient inhibition of the target enzyme is associated with inferior clinical responses, and have used this knowledge to modify clinical trial design for improved target modulation. We are currently developing assays for compounds targeting the PI3 kinase pathway and the MEK/AKT pathway and plan on incorporating these correlatives into upcoming clinical trials.
  • Leukemia

More Info

Languages
  • English
Clinical Trials
  • Leukemia
Additional Resources

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5464
U.S. 1-410-464-6713 (toll free)
International +1-410-614-6424

 

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer